NTRK 抑制剂在非小细胞肺癌中的挑战与机遇。
The Challenge and Opportunity of NTRK Inhibitors in Non-Small Cell Lung Cancer.
机构信息
Department of Hematology, Oncology and Bone Marrow Transplant, University of Minnesota, Minneapolis, MN 55455, USA.
出版信息
Int J Mol Sci. 2022 Mar 8;23(6):2916. doi: 10.3390/ijms23062916.
With the development of targeted therapy, non-small cell lung cancer (NSCLC) patients could have more treatment choices if target mutation presents. The neurotrophic tropomyosin receptor kinase (NTRK) has a low prevalence in NSCLC, roughly around 0.5%. FDA had approved two first generation NTRK inhibitors, larotrectinib and entrectinib. Both medications have excellent CNS penetration. This manuscript will review available data on targeting NTRK fusions in NSCLC and mechanisms of drug resistance.
随着靶向治疗的发展，如果存在靶点突变，非小细胞肺癌（NSCLC）患者将有更多的治疗选择。神经营养受体酪氨酸激酶（NTRK）在 NSCLC 中的发生率较低，约为 0.5%。FDA 已批准两种第一代 NTRK 抑制剂，拉罗替尼和恩曲替尼。这两种药物都有很好的中枢神经系统穿透性。本文将综述 NSCLC 中针对 NTRK 融合的现有数据和耐药机制。
Zotero 插件